


Laxido Module 3

Laxido Orange

For internal illustrative purposes only.
This module is for the UK market.

Laxido[®]

Macrogol 3350, sodium chloride,
sodium hydrogen carbonate, potassium chloride



Laxido Orange¹

Laxido Orange is an osmotic laxative and contains macrogol 3350 and electrolytes.

Therapeutic indication: For the treatment of chronic constipation. Laxido Orange is also effective in resolving faecal impaction, defined as refractory constipation with faecal loading of the rectum and/or colon. Laxido Orange is indicated in adults, adolescents and the elderly.

The group of macrogols that includes Laxido Orange is the only group of oral laxatives licensed for both chronic constipation and faecal impaction.²



How does Laxido Orange work?²



Composition of Laxido Orange¹

Active Ingredient	Amount per sachet
Macrogol 3350	13.125g
Sodium chloride	350.7mg
Sodium hydrogen carbonate (bicarbonate)	178.5mg
Potassium chloride	46.6mg
Electrolyte	Content following reconstitution*
Sodium	65mmol/l
Chloride	53mmol/l
Hydrogen carbonate (Bicarbonate)	17mmol/l
Potassium	5.4mmol/l

* In 125ml of water

Macrogol 3350³

n = 3350



n= measure of molecular mass;
larger number indicates higher molecular mass



Higher molecular weight macrogols e.g. macrogol 3350
undergo negligible absorption and metabolism



Reduced risk of adverse events and toxicity

Dosage and Administration¹

1. Pour the contents of one sachet of Laxido Orange into a glass
2. Add about half a glass of water (125ml)
3. Stir the mixture until the powder has dissolved
4. Drink the solution



You can prepare more than one sachet of Laxido Orange at a time, just allow 125ml of water for each sachet of Laxido Orange.

Faecal Softeners²


- Gastrointestinal tract effects most common
- Mild diarrhoea usually responds to dose reduction

System Organ Class	Adverse Event
Immune system disorders	Allergic reactions, including anaphylaxis, angioedema, dyspnoea, rash, urticaria, and pruritus.
Skin and subcutaneous tissue disorders	Erythema
Metabolism and nutrition disorders	Electrolyte disturbances, particularly hyperkalaemia and hypokalaemia.
Nervous system disorders	Headache
Gastrointestinal disorders	Abdominal pain, diarrhoea, vomiting, nausea, dyspepsia, abdominal distension, borborygmi, flatulence, anorectal discomfort.
General disorders	Peripheral oedema


Contraindications¹

Laxido Orange is contraindicated in:

- ✓ Intestinal obstruction or perforation caused by a functional or structural disorder of the gut wall
- ✓ Ileus
- ✓ Patients with severe inflammatory conditions of the intestinal tract e.g. ulcerative colitis, Crohn's disease and toxic megacolon
- ✓ Patients with hypersensitivity to the active substances or any of the excipients



Normal intestine



Intestinal blockage

Drug Interactions^{1,2,4}


- ✓ Theoretical possibility that absorption of other medicinal products could be reduced transiently
 - ✓ Isolated reports of decreased efficacy with some concomitantly administered medicinal products, e.g. anti-epileptics
 - ✓ Other medicines should not be taken orally for one hour before, or after, Laxido Orange
 - ✓ Laxido Orange may result in a potential interactive effect if used with starch-based food thickeners. The macrogol ingredient counteracts the thickening effect of starch, effectively liquefying preparations that need to remain thick for people with swallowing problems.
- 

Comparison with Movicol ^{1,4}


	Laxido Orange	Movicol
Macrogol 3350	13.125g	13.125g
Sodium chloride	350.7mg	350.7mg
Sodium hydrogen carbonate	178.5mg	178.5mg
Potassium chloride	46.6mg	46.6mg
Acesulfame potassium	✓	✓
Maltodextrin	✓	✓
Glucose	✗	✗

Clinical Data - Macrogol 3350 Efficacy Study^{5,6}

- Macrogol 3350 increased bowel movement vs placebo
- The greatest difference was at 2 weeks



Clinical Data - Attar 1999⁷



References

1. Laxido Orange, powder for oral solution. UK summary of Product Characteristics. Galen Limited. November 2021.
2. Ungar A. Movicol in treatment of constipation and faecal impaction. Hospital Medicine January 2000, 61 (1): 37-40.
3. Brayfield A, editor. Martindale The Complete Drug Reference 38th edition. London: The Pharmaceutical Press. 2014.
4. Movicol 13.8g sachet, powder for oral solution. Summary of Product Characteristics. Norgine Limited. April 2023.
5. The constipation conundrum: What now in chronic constipation and IBS-C? A self-study supplement to US. Pharmacist. September 2007.
6. DiPalma J et al. Overnight efficacy of polyethylene glycol laxative. The American Journal of Gastroenterology. 2002; 97(7): 1776-1779.
7. Attar A et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 1999; 44:226-230.